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Abstract
Background: Non-alcoholic fatty liver disease is the most common chronic liver disease in children in western
countries. Adverse early-life exposures are associated with higher liver fat percentages in children. Differential DNA
methylation may underlie these associations. We aimed to identify differential DNA methylation in newborns and
children associated with liver fat accumulation in childhood. We also examined whether DNA methylation at 22
cytosine-phosphate-guanine sites (CpGs) associated with adult non-alcoholic fatty liver disease is associated with
liver fat in children. Within a population-based prospective cohort study, we analyzed epigenome-wide DNA
methylation data of 785 newborns and 344 10-year-old children in relation to liver fat fraction at 10 years. DNA
methylation was measured using the Infinium HumanMethylation450 BeadChip (Illumina). We measured liver fat
fraction by Magnetic Resonance Imaging. Associations of single CpG DNA methylation at the two-time points with
liver fat accumulation were analyzed using robust linear regression models. We also analyzed differentially methylation
regions using the dmrff package. We looked-up associations of 22 known adult CpGs at both ages with liver fat at 10
years.
Results: The median liver fat fraction was 2.0% (95% range 1.3, 5.1). No single CpGs and no differentially methylated
regions were associated with liver fat accumulation. None of the 22 known adult CpGs were associated with liver fat in
children.
Conclusions: DNA methylation at birth and in childhood was not associated with liver fat accumulation in 10-year-old
children in this study. This may be due to modest sample sizes or DNA methylation changes being a consequence
rather than a determinant of liver fat.
Keywords: Non-alcoholic fatty liver disease, Liver steatosis, Epigenetics, Differentially methylated regions, Magnetic
resonance imaging
Background
Non-alcoholic fatty liver disease is a pathologic excess of
≥ 5% fat in hepatic cells, not caused by alcohol consump-
tion, genetic or metabolic disorders, medication, or viral
infections [1]. Due to the high prevalence of obesity,
non-alcoholic fatty liver disease has become the most
common chronic liver disease in both children and
adults in western countries [2–5]. Non-alcoholic fatty
liver disease is associated with an adverse cardio-
metabolic risk profile in children [3]. In adults, it is asso-
ciated with cardio-metabolic diseases and hepatocellular
carcinoma, and it is a leading indication for liver trans-
plantation [4, 6]. An accumulating body of evidence sug-
gests that adverse exposures in early life contribute to
the development of obesity and non-alcoholic fatty liver
disease [5, 7].
The mechanisms underlying the observed associations
of early-life factors with liver fat in children and adults
may include changes in DNA methylation [5, 7]. DNA
methylation is an epigenetic mechanism that is highly dy-
namic in early life and affects the accessibility of DNA for
transcription and thereby gene expression [8]. Various
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adverse early-life factors have been associated with
differential DNA methylation [9–12]. Recent studies
using liver biopsy samples of adults with non-
alcoholic fatty liver disease suggest differential DNA
methylation is cross-sectionally associated with non-
alcoholic fatty liver disease [8, 13–15]. A meta-
analysis of population-based cohorts in adults identi-
fied 22 cytosine-phosphate-guanine sites (CpGs) in
peripheral blood at which DNA methylation was asso-
ciated with non-alcoholic fatty liver disease [6].
We hypothesized that differential DNA methylation at
birth and in childhood is associated with liver fat accu-
mulation in children. We performed an epigenome-wide
association study (EWAS) to assess whether DNA
methylation at birth and at age 10 years is associated
with liver fat accumulation measured with magnetic res-
onance imaging (MRI) in 10-year-old children partici-
pating in a population-based prospective cohort study.
Analyses were focused on both single CpGs and differ-
entially DNA methylated regions (DMRs). As a second-
ary analysis, we examined if DNA methylation at birth
and at age 10 years is associated with higher (> 2%) ver-
sus lower (≤ 2%) liver fat accumulation. We also exam-
ined whether DNA methylation at the 22 CpGs known
to be associated with non-alcoholic fatty liver disease in
adults, is also associated with liver fat in children [6].
Results
Subject characteristics
The median liver fat fraction was 2.0% for both groups
(newborns 95% range 1.3, 4.6, 10-year-old children 95%
range 1.3, 5.1)). The prevalence of non-alcoholic fatty
liver disease at age 10 years was 2.2% (n = 17/785) in the
group with DNA methylation data at birth and 2.6% (n
= 9/344) in the group with DNA methylation data at age
10 years. The baseline characteristics of the study popu-
lation are presented in Table 1. Non-response analyses
comparing singleton children with DNA methylation
data, with and without information on liver fat fraction
available, showed that participants in the newborn group
were slightly more often female and more often over-
weight, had somewhat older and higher educated
mothers, who more often stopped smoking during preg-
nancy compared to non-participants in the newborn
group. In the childhood group, non-response analyses
showed that participants were slightly older compared to
non-participants (Table 2).
Epigenome-wide association study of childhood liver fat
accumulation
We assessed associations of DNA methylation in cord
blood and in whole peripheral blood at 10 years with
liver fat as a continuous measure in 10-year-old children.
Table 1 Subject characteristics
Newborns Childhood
(n = 785) (n = 344)
Maternal characteristics
Age, mean (SD), years 32.1 ± 4.0 32.1 ± 4.0
Prepregnancy body mass index, mean (SD), kg/m2 23.2 ± 3.9 23.4 ± 4.0
Parity, n (%), nulliparous 477 (60.8%) 205 (59.6%)
Education, n (%), higher education 535 (68.2%) 232 (67.4%)
Smoking during pregnancy, n (%), continued 94 (12.0%) 43 (12.5%)
Child characteristics
Gestational age at birth, median (95%), weeks 40.4 (37.0–42.3) 40.3 (36.9–42.4)
Age, mean (SD), years 0 9.8 ± 0.3
Males, n (%) 378 (48.2%) 170 (49.4%)
Birth weight, mean (SD), g 3556 ± 505 3578 ± 515
Body mass index at 10 years, mean (SD), kg/m2 17.0 ± 2.1 17.1 ± 2.0
Children with
Underweight, n (%) 62 (7.9) 19 (5.5)
Normal weight, n (%) 637 (81.1) 287 (83.4)
Overweight, n (%) 79 (10.1) 37 (10.8)
Obesity, n (%) 7 (0.9) 1 (0.3)
Liver fat fraction, median (95% range), % 2.0 (1.3–4.6) 2.0 (1.3–5.1)
Prevalence non-alcoholic fatty liver disease, n (%) 17 (2.2%) 9 (2.6%)
Values are observed data and represent means ± SD, medians (95% range), or numbers of subjects (valid %)
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In the main models, adjusted for maternal age, education
level, early-pregnancy BMI and smoking, gestational age
at birth (cord blood analyses) or child age (childhood
analyses), child sex, cell-type proportions, and batch, we
did not observe any CpGs at birth or at 10 years to be
associated with liver fat accumulation at 10 years after
Bonferroni (p value < 1.0 × 10−7) or false-discovery rate
(FDR) correction. The Manhattan plots of both EWAS
analysis of liver fat accumulation are presented in
Additional file 1: Figure S1a and Figure S1b. Additional
file 2: Table S1 and Table S2 show the CpGs with p
values < 1.0 × 10−4 for newborns and for 10-year-old
children, respectively. We did not identify significantly
associated differentially methylated regions associated
with liver fat accumulation, nor did we find associations
of individual CpG sites with higher versus lower liver fat
accumulation. Additional file 3: Table S3 and Table S4
show the differentially methylated regions with p values
< 1.0 × 10−4 for newborns and 10-year-old children, re-
spectively. Additional file 4: Table S5 and Table S6 show
the CpGs with p values < 1.0 × 10−4 for newborns and
for 10-year-old children for higher versus lower liver fat,
respectively. Results of the basic model and of the model
additionally adjusted for childhood body mass index
(BMI) were not substantially different from the results in
the main model. The mean percent differences in effect
estimates between the main model and the basic model,
and between the main model and the childhood BMI
model in cord blood were 2.5% and 10.9%, respectively.
In the child peripheral blood analyses at 10 years, the
mean percent differences were 1.6% and 3.9%, respect-
ively. In Additional file 5: Table S7 and Table S8, we
show the results of the basic and childhood BMI models
for the CpGs probes with p values < 1.0 × 10−4 identified
in the main model.
Look-up of CpGs associated with adult liver fat
None of the 22 CpGs differentially methylated regions
known for their associations with non-alcoholic fatty
liver disease in adults were associated with liver fat in
children (Bonferroni corrected p value cutoff < 0.05/22 =
2.3 × 10−3, Table 3). We found no evidence for enrich-
ment of the 22 CpGs among the 18,848 nominally sig-
nificant CpGs from the cord blood analysis and among
the 23,173 nominally significant CpGs from the 10-year-
old analysis (Fisher combined probability p value = 1.00
in newborns and p value = 0.68 in 10-year-old children).
Candidate genes analysis associated with liver fat
We examined if there was an enrichment of CpGs lo-
cated in regions within a 4 Mb window (± 2 Mb) sur-
rounding the 9 single-nucleotide polymorphisms (SNPs)
Table 2 Comparison of child characteristics between children included and not included in the analyses
Newborns participants Non-participants P value Children
participants
Non-
participants
P value
(n = 785) (n = 604) (n = 344) (n = 120)
Maternal characteristics
Age, mean (SD), years 32.1 ± 4.0 31.3 ± 4.5 <0.01 32.1 ± 4.0 32.5 ± 4.1 0.41
Prepregnancy body mass index, mean (SD), kg/m2 23.2 ± 3.9 23.2 ± 3.8 0.95 23.4 ± 4.0 22.7 ± 3.2 0.12
Parity, n (%), nulliparous 477 (60.8%) 365 (60.6%) 0.96 205 (59.6%) 73 (61.3%) 0.74
Education, n (%), higher education 535 (68.2%) 357 (61.1%) <0.01 232 (67.4%) 75 (65.2%) 0.86
Smoking during pregnancy, n (%), continued 94 (12.0%) 88 (18.0%) <0.01 43 (12.5%) 8 (9.3%) 0.70
Child characteristics
Gestational age at birth, median (95%), weeks 40.4 (37.0–42.3) 40.3 (36.3 – 42.4) 0.45 40.3 (36.9 – 42.4) 40.4 (37.6–42.4) 0.63
Age, mean (SD), years NA NA NA 9.8 ± 0.3 9.7 ± 0.3 <0.01
Males, n (%) 378 (48.2%) 325 (53.8%) 0.04 170 (49.4%) 61 (50.8%) 0.79
Birth weight, mean (SD), g 3556 ± 505 3528 ± 518 0.31 3578 ± 515 3547 ± 498 0.57
Body mass index, mean (SD), kg/m2 17.0 ± 2.1 17.0 ± 2.1 0.77 17.1 ± 2.0 17.2 ± 2.2 0.62
Children with
Underweight, n (%) 62 (7.9) 30 (8.1) 0.12 19 (5.5) 8 (6.7) 0.21
Normal weight, n (%) 637 (81.1) 299 (80.6) 0.05 287 (83.4) 97 (80.8) 0.42
Overweight, n (%) 79 (10.1) 38 (6.3) 0.01 37 (10.8) 13 (10.8) 0.52
Obesity, n (%) 7 (0.9) 4 (0.7) 0.09 1 (0.3) 2 (1.7) 0.11
Values are observed data and represent means ± SD, medians (95% range), or numbers of subjects (valid %). Differences were tested using Student’s t tests and
Mann-Whitney tests for normally and non-normally distributed variables, respectively and using χ2-test for dichotomous variables
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identified to be associated with non-alcoholic fatty liver
disease in adults, among all nominally significant CpGs
in our analyses [16, 17]. A total of 7225 CpGs were
present in these regions in the newborn dataset and
7244 CpGs in the 10-year-old dataset. In newborns, 299
of these CpGs were nominally significant (p value <
0.05). In 10-year-old children, this was the case for 347
CpGs. There was no enrichment for CpGs associated
with liver fat accumulation at either age (Fisher com-
bined probability p value = 0.47 in newborns and p value
= 0.86 in 10-year-old children).
Top CpG probes functions and related biological processes
In an explorative analysis, significantly enriched gene
ontology (GO) terms based on the annotated genes of
the 32 CpG probes with p values < 1.0 × 10−4 in cord
blood pointed towards processes related to triglyceride,
acylglycerol and lipid metabolic processes, digestive tract
development, digestive system development, and digest-
ive tract morphogenesis, among others (Additional file 6:
Table S9). The same analysis using the 76 CpG probes
with p values < 1.0 × 10−4 in child peripheral blood re-
vealed processes related to cell cycle functions, organ mor-
phogenesis, and development, among others (Additional
file 6: Table S10). We did not observe the functional en-
richment of Kyoto Encyclopedia of Genes and Genomes
(KEGG) terms ((FDR < 0.05). Next to this, we did not ob-
serve significant enrichment of DNAse hypersensitivity
sites among the CpG probes with p values < 1.0 × 10−4
(smallest p value in cord blood analyses 0.09 and in child-
hood analyses 0.25).
Discussion
In the first epigenome-wide association study on liver fat
accumulation in children, we did not observe differential
DNA methylation in newborns or 10-year-old children
related to liver fat accumulation analyzed as a continu-
ous measure or related to higher versus lower liver fat
accumulation measured by MRI at age 10 years. Also,
DNA methylation at 22 CpGs known to be associated
with non-alcoholic fatty liver disease in adults was not
associated with liver fat in children.
Table 3 Associations of 22 adult non-alcoholic fatty liver disease-associated CpGs with liver fat fraction in children
Newborns Children
CpG Chromosome Position Gene Effect* SE* P value Effect* SE* P value
cg09469355 1 2161886 SKI 0.002 0.03 0.96 − 0.002 0.07 0.98
cg17901584 1 55353706 DHCR24 − 0.005 0.02 0.74 − 0.069 0.04 0.08
cg03725309 1 109757585 SARS − 0.012 0.02 0.45 0.027 0.05 0.56
cg14476101 1 120255992 PHGDH − 0.003 0.02 0.99 0.011 0.04 0.78
cg19693031 1 145441552 TXNIP − 0.011 0.03 0.72 − 0.031 0.04 0.45
cg06690548 4 139162808 SLC7A11 − 0.086 0.05 0.08 − 0.027 0.06 0.67
cg05119988 4 166251189 SC4MOL 0.003 0.02 0.88 0.003 0.03 0.92
cg03957124 6 37016869 COX6A1P2** 0.011 0.02 0.59 0.027 0.05 0.58
cg18120259 6 43894639 LOC100132354** 0.024 0.02 0.31 − 0.124 0.05 0.02
cg17501210 6 166970252 RPS6KA2 0.086 0.07 0.21 − 0.137 0.08 0.10
cg21429551 7 30635762 GARS 0.015 0.02 0.42 0.017 0.03 0.52
cg11376147 11 57261198 SLC43A1 − 0.004 0.03 0.89 0.107 0.07 0.11
cg00574958 11 68607622 CPT1A 0.028 0.04 0.43 − 0.019 0.08 0.79
cg26894079 11 122954435 ASAM 0.004 0.03 0.88 − 0.020 0.04 0.63
cg11024682 17 17730094 SREBF1 − 0.023 0.04 0.54 − 0.005 0.07 0.93
cg14020176 17 72764985 SLC9A3R1 0.006 0.03 0.84 − 0.007 0.06 0.90
cg19016694 17 80821826 TBCD 0.016 0.03 0.55 − 0.062 0.06 0.30
cg15860624 19 3811194 ZFR2 0.011 0.02 0.61 0.002 0.05 0.97
cg02711608 19 47287964 SLC1A5 − 0.025 0.03 0.44 0.004 0.06 0.95
cg08309687 21 35320596 LINC00649** − 0.004 0.03 0.88 − 0.008 0.04 0.84
cg27243685 21 43642366 ABCG1 0.042 0.04 0.32 − 0.023 0.09 0.81
cg06500161 21 43656587 ABCG1 0.018 0.03 0.57 0.023 0.05 0.66
*Effect estimates represent the change in liver fat fraction (%) per 10% difference in DNA methylation beta and standard error. Associations are adjusted for
maternal age, education level, early-pregnancy BMI and smoking, age at birth or child age at measurement, child sex, cell type proportions, and batch. *Gene
names added using information from the UCSC Genome Browser build hg19. Other gene names from original paper by Ma et al. 2019. BMI body mass index,
n number, SE standard error
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Interpretation of main findings
Non-alcoholic fatty liver disease has an increasing preva-
lence in both children and adults [5, 18]. It is a major risk
factor for adverse cardio-metabolic health in children and
for cardio-metabolic diseases and liver diseases in adults
[3, 4, 6]. Adverse early-life factors have been described to
be associated with liver fat development [5, 7]. These asso-
ciations may be explained by DNA methylation changes
in response to these early-life exposures that lead to liver
fat development [5, 19].
Among adults, it has been demonstrated that differential
DNA methylation is present in liver biopsy samples of
adults with non-alcoholic fatty liver disease [8, 13–15, 20].
All these studies used liver histology, the current gold
standard for diagnosing non-alcoholic fatty liver disease
[2, 5]. As a consequence, these studies are limited by small
sample sizes, histologically heterogeneous groups varying
in the severity of the non-alcoholic fatty liver disease,
older study populations, wide BMI ranges, and having
only few or no healthy controls. None of these reports
controlled for cell heterogeneity in their analyses. A recent
meta-analysis of four multiethnic population-based cohort
studies in adults showed that DNA methylation at 22
CpGs in peripheral blood was associated with non-
alcoholic fatty liver disease diagnosed with either com-
puted tomography or ultrasound imaging (FDR < 0.05)
[6]. In this study, in newborns and 10-year-old children
we did not observe differential DNA methylation at single
CpGs or differentially methylated regions in cord blood or
child peripheral blood in association with MRI diagnosed
liver fat accumulation in 10-year-old children. The associ-
ations of the 22 CpGs identified in adults could also not
be replicated in children [6]. It is possible that small, but
potentially biologically important DNA methylation differ-
ences may be associated with liver fat accumulation in
children. These differences would be difficult to detect in
the moderate sample size of the current study. Besides
this, the variability in liver fat accumulation in this popula-
tion of children was relatively small, which may also partly
explain the lack of identified associations. In addition, our
study population is a relatively lean population. Associa-
tions of DNA methylation with liver fat accumulation may
be more apparent among higher-risk populations, as ob-
served in adult studies [8, 13–15, 20]. Another possibility
is that DNA methylation truly is not associated with liver
fat accumulation in children. As has been suggested for
phenotypes such as obesity, differential DNA methylation
may be mostly a consequence rather than a cause of liver
fat accumulation. If that is indeed the case, then the dur-
ation of exposure to increased liver fat in this population
of 10-year-old children may not have been sufficient to in-
duce differential DNA methylation [21].
The present population-based study is the first to
examine the association of differential DNA methylation
with liver fat fraction measured with MRI in children.
Although the hypothesis of early-life factors contributing
to the development of liver fat accumulation through
DNA methylation cannot be completely discarded based
on this study, we found no evidence to support associa-
tions of differential DNA methylation in newborns or
children with liver fat accumulation at 10 years. Future
studies should investigate in large longitudinal studies
the associations of differential DNA methylation with
liver fat accumulation in children.
Methodological considerations
The strengths of this study are the prospective and
cross-sectional analyses with information on DNA
methylation at two ages. We used a sensitive imaging-
based method to enable non-invasive measurement of
liver fat [22, 23]. Although our sample size is relatively
large for epigenome-wide analyses, it might still be too
small to detect more minor effect sizes [8, 13–15]. We
identified no Bonferonni or FDR significant associations
for differential DNA methylation in cord blood and in
child peripheral blood at 10 years to be associated with
liver fat accumulation in childhood. Therefore, the path-
way analyses based on the annotated genes of the CpG
probes with p values < 1.0 × 10−4 need to be carefully
interpreted. Many of the enriched pathways are based
on a relatively low number of genes. As such, the results
of the pathway analysis should be considered exploratory
and need further confirmation. To the best of our know-
ledge, similar data on DNA methylation and MRI-
measured liver fat accumulation in children are not cur-
rently available elsewhere. DNA methylation was mea-
sured in blood, which may differ from DNA methylation
in liver cells. The relatively small number of children
with obesity in the included sample indicates a selection
towards a lean population that may affect the
generalizability of our findings.
Conclusions
DNA methylation at birth and in childhood was not as-
sociated with liver fat accumulation in 10-year-old chil-
dren in this study. This may be due to modest sample
sizes or DNA methylation changes being a consequence
rather than a determinant of liver fat. Future studies
should investigate in large longitudinal studies the asso-
ciations and timing of differential DNA methylation with
liver phenotypes in children.
Methods
Study design
This study was embedded in the Generation R Study, a
population-based prospective cohort from early fetal life
onwards, based in Rotterdam, the Netherlands [24]. The
study has been approved by the Medical Ethical Committee
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of the Erasmus MC, University Medical Center Rotterdam
(MEC 198.782/2001/31). Written informed consent was
obtained for all participants [24]. All 9778 participating
live-born children were born between April 2002 and Janu-
ary 2006. DNA methylation was measured in a randomly
selected European-ancestry subset of 1396 newborns and
464 10-year-old children. The liver fat MRI measurements
were performed in a subgroup of children at age 10 years.
We excluded children without complete data on liver fat
fraction and covariates. The population for analysis of this
study comprised 785 newborns and 344 10-year-old chil-
dren (Fig. 1).
DNA methylation
DNA was extracted from cord blood and whole peripheral
blood at 10 years using the salting-out method. Five hun-
dred nanograms of DNA per sample underwent bisulfite
conversion using the EZ-96 DNA Methylation kit (Shal-
low) (Zymo Research Corporation, Irvine, CA, USA).
Samples were plated randomly onto 96-well plates. Sam-
ples were processed with the Illumina Infinium Human-
Methylation450 (450k) BeadChip (Illumina Inc., San
Diego, CA, USA). Quality control of analyzed samples was
performed using standardized criteria. Quality control and
normalization of the HumanMethylation450 BeadChip
array data was performed according to the Control Probe
Adjustment and reduction of global CORrelation (CPA-
COR) workflow using R [25, 26]. Probes that had a detec-
tion p value ≥ 1E− 16 were set to missing per array. Next,
the intensity values were quantile normalized for each of
the six probe-type categories separately: type II red/green,
type I methylated red/green, and type I unmethylated red/
green. Beta values were calculated as the proportion of
methylated intensity value to the sum of methylated and
unmethylated intensities plus 100. Arrays with observed
technical problems such as failed bisulfite conversion,
hybridization or extension, as well as arrays with a sex
mismatch were removed from subsequent analyses.
Additionally, only arrays with a call rate > 95% per
sample were processed further. Probes on the X and
Y chromosomes were excluded from the analyses.
The final datasets contained 457,774 probes in the
newborn dataset and 458,563 probes in the 10-year-
old dataset. For all CpGs and differentially methylated
regions, the official gene name of the nearest gene
was noted using Illumina’s annotation information
and we enhanced the annotation provided by Illumina
with the UCSC Genome Browser build hg19 [27, 28].
Fig. 1 Study participants flow chart
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Liver fat fraction at 10 years
We measured liver fat using a 3.0 Tesla MRI (Discovery
MR750w, GE Healthcare, Milwaukee, WI, USA) [1, 22–24].
The children wore light clothing without metal objects
while undergoing the body scan. A liver fat scan was per-
formed using a single-breath-hold, 3D volume and a special
3-point proton density-weighted Dixon technique (IDEAL
IQ) for generating a precise liver fat fraction image [29].
The IDEAL IQ scan is based on a carefully tuned 6-echo
echo-planar imaging acquisition. The obtained fat-fraction
maps were subsequently analyzed by the Precision Image
Analysis (PIA, Kirkland, WA, USA) using the sliceOmatic
(TomoVision, Magog, QC, CAN) software package. All ex-
traneous structures and any image artifacts were removed
manually [30]. The liver fat fraction was measured inde-
pendent of any outcome, determined by taking four sam-
ples of at least 4 cm2 from the central portion of the
hepatic volume. Subsequently, the mean signal intensities
were averaged to generate an overall mean liver fat fraction
estimation. Liver fat fraction measured with IDEAL IQ
using MRI is reproducible, highly precise, and validated in
adults [31, 32]. As previously described, non-alcoholic fatty
liver disease was defined as liver fat fraction ≥ 5.0%
[1, 32, 33]. We studied liver fat accumulation across
the full spectrum as our primary objective. As the
secondary objective, we dichotomized liver fat into
low, ≤ 2.0%, and high, > 2.0%, liver fat accumulation.
This cutoff was based on the median in our popula-
tion and on previous work from our group describing
that liver fat accumulation above 2.0% is already asso-
ciated with an increased cardio-metabolic risk profile
in children [34]. Due to the lower numbers of cases,
we could not dichotomize liver fat accumulation
based on the clinical cutoff of ≥ 5.0%.
Covariates
At enrolment in the study, information on maternal age
and educational level was obtained by questionnaires.
Maternal smoking during pregnancy was assessed by
questionnaires in pregnancy. We measured maternal
height and weight at enrolment to calculate early-
pregnancy BMI [35]. Information on gestational age at
birth, child sex, and age at 10 years visit was obtained
from medical records. We measured height and weight
in the children, without shoes and heavy clothing. Child-
hood BMI was calculated and sex- and age-adjusted
childhood BMI standard deviation scores were calcu-
lated (Growth Analyzer 4.0, Dutch Growth Research
Foundation) [36].
Look-up study of adult CpGs associated with liver fat
We examined in our data the associations of the 22
CpGs known from previous literature to be associated
with liver fat accumulation in adults with liver fat
accumulation in children [6]. A Bonferroni corrected p
value < 0.05/22 = 2.3 × 10−3 was used to define signifi-
cance. We also evaluated whether the 22 CpGs were
enriched among CpGs with a p < 0.05 in our results
using a hypergeometric test.
Genes previously associated with liver fat
We assessed the number of nominally significant sin-
gle CpGs from our analyses that were located within
a 4 Mb window (± 2 Mb) surrounding the 9 SNPs
identified in 2 previous genome-wide association
studies (GWAS) of liver fat accumulation in adoles-
cents and adults of European descent [16, 17]. With
a hypergeometric test, we calculated enrichment of
the CpGs surrounding the 9 SNPs among CpGs with
a p < 0.05 in our results.
Pathway analysis
To identify biological processes associated with the genes
annotated to the CpG probes with p values < 1.0 × 10−4
identified in cord blood and in child peripheral blood at
10 years associated with liver fat accumulation, we used
the DAVID version 6.8 released October 2016 bioinfor-
matics resource to test for enrichment in GO biological
processes and KEGG pathways [37]. The online program
epigenetic Functional element Overlap analysis of the Re-
sults of Genome-Wide Association Study Experiments
(eFORGE) was used to examine enrichment for DNAse
hypersensitivity site enrichment among the most signifi-
cantly associated CpGs in both cord blood and in child
peripheral blood at 10 years [38].
Statistical analysis
First, non-response analysis was conducted among
singleton children with DNA methylation data, and with
or without complete data on liver fat and covariates
available, using Student’s t tests, Mann-Whitney tests,
and chi-square tests. Second, we used robust linear re-
gression models to assess the associations of DNA
methylation in cord blood and in whole peripheral blood
at 10 years with liver fat fraction as a continuous meas-
ure in 10-year-old children [26]. The analyses were per-
formed in three models, namely, a basic model (adjusted
for gestational age at birth, child sex, cell type propor-
tions, and batch), a main model (additionally adjusted
for maternal age, education level, early-pregnancy BMI,
and smoking), and a childhood BMI model (additionally
adjusted for childhood BMI at 10 years). The statistical
models for DNA methylation measured in 10-year-old
children were the same, with the only difference that
they were adjusted for child age at the time of measure-
ment instead of gestational age at birth. We adjusted for
leukocyte subtypes using the cord blood-specific Gervin
reference for the cord blood analyses and the Reinius
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reference set for the analyses at 10 years using the minfi
Bioconductor package in R [39–42]. Included covariates
were based on previous studies and strong correlations
with DNA methylation and liver fat [2, 6]. Since the out-
come of liver fat had a skewed distribution, it was nat-
ural log-transformed. Multiple testing was accounted for
using Bonferroni correction, with CpGs with a p value <
1.0 × 10−7 considered significant. Additionally, we
planned to report results using FDR correction for mul-
tiple testing, using the method by Benjamini and Hoch-
berg [43]. Third, we identified differentially methylated
regions using the dmrff package (https://github.com/per
ishky/dmrff), which identifies differentially methylated
regions by combining EWAS summary statistics from
nearby CpGs [44]. Significant differentially methylated
regions were defined based on the following criteria:
(1) within one differentially methylated region, the
distance between two neighboring probes can be at
most 500 base pairs; (2) the regions have nominal
EWAS p values < 0.05, and (3) EWAS effect estimates
for the individual CpGs in a differentially methylated
regions have the same direction. All analyses were
performed using R version 3.4.3 [26]. All authors had
access to the study data and reviewed and approved
the final manuscript.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-019-0799-6.
Additional file 1: Figure S1a. Epigenome-wide Association Study
Results of DNA Methylation in Cord Blood with Liver Fat Fraction in
Children. Figure S1b. Epigenome-wide Association Study Results of DNA
Methylation in Child Peripheral Blood with Liver Fat Fraction in Children.
Additional file 2: Table S1. CpG with p-values <1.0 × 10-4 from
Epigenome-wide Association Study of DNA Methylation in Cord Blood
and Child Liver Fat Accumulation in Childhood*. Table S2. CpG with
p-values <1.0 × 10-4 from Epigenome-wide Association Study of DNA
Methylation in Child Peripheral Blood with Liver Fat Accumulation in
Childhood*.
Additional file 3: Table S3. Differentially Methylated Regions with p-
values <1.0 × 10-4 of DNA Methylation in Cord Blood with Liver Fat
Accumulation in Childhood*. Table S4. Differentially Methylated Regions
with p-values <1.0 × 10-4 of DNA Methylation in Child Peripheral Blood
with Liver Fat Accumulation in Childhood*.
Additional file 4: Table S5. CpGs with p-values <1.0 × 10-4 from
Epigenome-wide Association Study of DNA Methylation in Cord Blood
with Higher versus Lower Liver Fat Accumulation in Childhood*. Table
S6. CpGs with p-values <1.0 × 10-4 from Epigenome-wide Association
Study of DNA Methylation in Child Peripheral Blood with Higher versus
Lower Liver Fat Accumulation in Childhood*.
Additional file 5: Table S7. Results of Basic Model and Child BMI
Model for CpGs with p-values <1.0 × 10-4 in Main Model in Cord Blood*.
Table S8. Results of Basic Model and Child BMI Model for CpGs with
p-values <1.0 × 10-4 in Main Model in Child Peripheral Blood*.
Additional file 6: Table S9. Significantly enriched GO terms among
CpGs with p-values <1.0 × 10-4 Identified in Cord Blood Associated with
Liver Fat Accumulation in Childhood. Table S10. Significantly enriched
GO terms among CpGs with p-values <1.0 × 10-4 Identified in Child
Peripheral Blood Associated with Liver Fat Accumulation in Childhood.
Abbreviations
BMI: Body mass index; CpGs: Cytosine-phosphate-Guanine sites;
eFORGE: Epigenetic Functional element Overlap analysis of the Results of
Genome-Wide Association Study Experiments; EWAS: Epigenome-wide
association study; FDR: False-discovery rate; GO: Gene ontology; KEGG: Kyoto
Encyclopedia of Genes and Genomes; MRI: Magnetic Resonance Imaging;
SNPs: Single-nucleotide polymorphisms
Acknowledgements
The Generation R Study is conducted by the Erasmus Medical Center in
close collaboration with the School of Law and Faculty of Social Sciences of
the Erasmus University Rotterdam, the Municipal Health Service Rotterdam
area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam and the
Stichting Trombosedienst and Artsenlaboratorium Rijnmond (STAR-MDC),
Rotterdam. We gratefully acknowledge the contribution of children and
parents, general practitioners, hospitals, midwives, and pharmacies in
Rotterdam. The study protocol was approved by the Medical Ethical
Committee of the Erasmus Medical Centre, Rotterdam. Written informed
consent was obtained for all participants. The generation and management
of the Illumina 450K methylation array data (EWAS data) for the Generation R
Study was executed by the Human Genotyping Facility of the Genetic
Laboratory of the Department of Internal Medicine, Erasmus MC, the
Netherlands. We thank Mr. Michael Verbiest, Ms. Mila Jhamai, Ms. Sarah
Higgins, Mr. Marijn Verkerk, and Dr. Lisette Stolk for their help in creating the
EWAS database. We thank Dr. A. Teumer for his work on the quality control
and normalization scripts.
Authors’ contributions
MLG was responsible for the study concept and design, acquisition of the
data, statistical analyses and interpretation of data, and drafting of the
manuscript. VWVJ was responsible for the study concept and design,
acquiring and interpreting data, obtaining funding, and critical revision of
the manuscript for important intellectual content. LAS was responsible for
analyzing the data and critical revision of the manuscript for important
intellectual content. SS was responsible for drafting the manuscript and
critical revision of the manuscript for important intellectual content. JFF was
responsible for the study concept and design, statistical analysis and
interpretation of the data, obtaining funding, and critical revision of the
manuscript for important intellectual content. All authors read and approved
the final manuscript.
Funding
The general design of the Generation R Study is made possible by financial
support from the Erasmus Medical Center, Rotterdam, the Erasmus University
Rotterdam, the Netherlands Organization for Health Research and Development
and the Ministry of Health, Welfare and Sport. The EWAS data was funded by a
grant to VWVJ from the Netherlands Genomics Initiative (NGI)/Netherlands
Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy
Aging (NCHA; project number 050-060-810), by funds from the Genetic Laboratory
of the Department of Internal Medicine, Erasmus MC, and by a grant from the
National Institute of Child and Human Development (R01HD068437). VWVJ
received a grant from the Netherlands Organization for Health Research and
Development (VIDI 016.136.361) and a Consolidator Grant from the European
Research Council (ERC-2014-CoG-648916). This project received funding from the
European Union’s Horizon 2020 research and innovation programme (733206,
LIFECYCLE) and from the European Joint Programming Initiative “A Healthy Diet
for a Healthy Life” (JPI HDHL, NutriPROGRAM project, ZonMw the Netherlands
no.529051022).
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study has been approved by the Medical Ethical Committee of the
Erasmus MC, University Medical Center Rotterdam (MEC 198.782/2001/31).
Written informed consent was obtained for all participants [24].
Consent for publication
Not applicable.
Geurtsen et al. Clinical Epigenetics            (2020) 12:3 Page 8 of 10
Competing interests
The authors declare that they have no competing interests.
Author details
1The Generation R Study Group, Erasmus MC, University Medical Center
Rotterdam, PO Box 2040, Rotterdam 3000 CA, the Netherlands. 2Department
of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam,
the Netherlands. 3Geisel School of Medicine at Dartmouth, Hanover, New
Hampshire, USA.
Received: 16 October 2019 Accepted: 19 December 2019
References
1. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al.
NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of
Nonalcoholic Fatty Liver Disease in Children: Recommendations from the
Expert Committee on NAFLD (ECON) and the North American Society of
Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr
Gastroenterol Nutr. 2017;64(2):319–34.
2. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The
prevalence of non-alcoholic fatty liver disease in children and adolescents: a
systematic review and meta-analysis. PLoS One. 2015;10(10):e0140908.
3. Schwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow
KE, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty
liver disease in adolescent boys: a randomized clinical trial. Jama. 2019;
321(3):256–65.
4. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;
15(1):45.
5. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic
steatohepatitis. N Engl J Med. 2017;377(21):2063–72.
6. Ma J, Nano J, Ding J, Zheng Y, Hennein R, Liu C, et al. A peripheral blood
DNA methylation signature of hepatic fat reveals a potential causal pathway
for non-alcoholic fatty liver disease. Diabetes. 2019.
7. Ayonrinde OT, Oddy WH, Adams LA, Mori TA, Beilin LJ, de Klerk N, et al.
Infant nutrition and maternal obesity influence the risk of non-alcoholic
fatty liver disease in adolescents. J Hepatol. 2017;67(3):568–76.
8. Gerhard GS, Malenica I, Llaci L, Chu X, Petrick AT, Still CD, et al. Differentially
methylated loci in NAFLD cirrhosis are associated with key signaling
pathways. Clin Epigenetics. 2018;10(1):93.
9. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA
methylation in newborns and maternal smoking in pregnancy: genome-
wide consortium meta-analysis. Am J Hum Genet. 2016;98(4):680–96.
10. Sharp GC, Salas LA, Monnereau C, Allard C, Yousefi P, Everson TM, et al.
Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA
methylation: findings from the pregnancy and childhood epigenetics
(PACE) consortium. Hum Mol Genet. 2017;26(20):4067–85.
11. Rider CF, Carlsten C. Air pollution and DNA methylation: effects of exposure
in humans. Clin Epigenetics. 2019;11(1):131.
12. James P, Sajjadi S, Tomar AS, Saffari A, Fall CHD, Prentice AM, et al.
Candidate genes linking maternal nutrient exposure to offspring health via
DNA methylation: a review of existing evidence in humans with specific
focus on one-carbon metabolism. Int J Epidemiol. 2018;47(6):1910–37.
13. de Mello VD, Matte A, Perfilyev A, Mannisto V, Ronn T, Nilsson E, et al.
Human liver epigenetic alterations in non-alcoholic steatohepatitis are
related to insulin action. Epigenetics. 2017;12(4):287–95.
14. Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, Abdelmalek MF, et al.
Relationship between methylome and transcriptome in patients with
nonalcoholic fatty liver disease. Gastroenterology. 2013;145(5):1076–87.
15. Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T, et al.
DNA methylation analysis in nonalcoholic fatty liver disease suggests
distinct disease-specific and remodeling signatures after bariatric surgery.
Cell Metab. 2013;18(2):296–302.
16. Adams LA, White SW, Marsh JA, Lye SJ, Connor KL, Maganga R, et al.
Association between liver-specific gene polymorphisms and their
expression levels with nonalcoholic fatty liver disease. Hepatology. 2013;
57(2):590–600.
17. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD,
et al. Genome-wide association analysis identifies variants associated with
nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
PLoS Genet. 2011;7(3):e1001324.
18. Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and
monitoring non-alcoholic fatty liver disease in adults. Bmj. 2018;362:k2734.
19. Gabory A, Attig L, Junien C. Developmental programming and epigenetics.
Am J Clin Nutr. 2011;94(suppl_6):1943S–52S.
20. Hotta K, Kitamoto A, Kitamoto T, Ogawa Y, Honda Y, Kessoku T, et al.
Identification of differentially methylated region (DMR) networks associated
with progression of nonalcoholic fatty liver disease. Sci Rep. 2018;8(1):13567.
21. Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-wide
association study of body mass index, and the adverse outcomes of
adiposity. Nature. 2017;541(7635):81–6.
22. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US,
CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with
liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87–97.
23. Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN,
et al. Magnetic resonance imaging and liver histology as biomarkers of
hepatic steatosis in children with nonalcoholic fatty liver disease.
Hepatology. 2015;61(6):1887–95.
24. Kooijman MN, Kruithof CJ, van Duijn CM, Duijts L, Franco OH, van IMH, et al.
The Generation R Study: design and cohort update 2017. Eur J Epidemiol.
2016;31(12):1243–64.
25. Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan ST, et al. A coherent
approach for analysis of the Illumina HumanMethylation450 BeadChip
improves data quality and performance in epigenome-wide association
studies. Genome Biol. 2015;16:37.
26. R Core Team. R: A language and environment for statistical computing.
2014(R Foundation for Statistical Computing, Vienna, Austria.).
27. Triche T. FDb.InfiniumMethylation.hg19: annotation package for Illumina
Infinium DNA methylation probes. R package version 220. 2014.
28. Infinium HumanMethylation450K v1.2 Product Files. 2014. http://support.
illumina.com/downloads/infinium_humanmethylation450_product_files.html.
29. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat
with magnetic resonance imaging and spectroscopy. J Magn Reson
Imaging. 2011;34(4):spcone.
30. Hu HH, Nayak KS, Goran MI. Assessment of abdominal adipose tissue and
organ fat content by magnetic resonance imaging. Obes Rev. 2011;12(5):
e504–15.
31. Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and
recommendations for imaging liver fat in children, based on systematic
review. Clin Gastroenterol Hepatol. 2014;12(5):765–73.
32. Petaja EM, Yki-Jarvinen H. Definitions of normal liver fat and the association
of insulin sensitivity with acquired and genetic NAFLD-A systematic review.
Int J Mol Sci. 2016;17:5.
33. Newton KP, Hou J, Crimmins NA, Lavine JE, Barlow SE, Xanthakos SA, et al.
Prevalence of prediabetes and type 2 diabetes in children with
nonalcoholic fatty liver disease. JAMA Pediatr. 2016;170(10):e161971.
34. Geurtsen ML, Santos S, Felix JF, Duijts L, Vernooij MW, Gaillard R, et al. Liver
fat and cardio-metabolic risk factors among school age children.
Hepatology. 2019.
35. Jaddoe VW, van Duijn CM, Franco OH, van der Heijden AJ, van Iizendoorn
MH, de Jongste JC, et al. The Generation R Study: design and cohort update
2012. Eur J Epidemiol. 2012;27(9):739–56.
36. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index
measurements in 1996-7 compared with 1980. Arch Dis Child. 2000;82(2):
107–12.
37. Huang Da W, Sherman BT, Lempicki RA. Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;
4(1):44–57.
38. Breeze CE, Reynolds AP, van Dongen J, Dunham I, Lazar J, Neph S, et al.
eFORGE v2.0: updated analysis of cell type-specific signal in epigenomic
data. Bioinformatics. 2019;35(22):4767–9.
39. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ,
Nelson HH, et al. DNA methylation arrays as surrogate measures of cell
mixture distribution. BMC Bioinformatics. 2012;13:86.
40. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen
KD, et al. Minfi: a flexible and comprehensive bioconductor package for the
analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;
30(10):1363–9.
41. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, et al.
Differential DNA methylation in purified human blood cells: implications for
cell lineage and studies on disease susceptibility. PLoS One. 2012;7(7):
e41361.
Geurtsen et al. Clinical Epigenetics            (2020) 12:3 Page 9 of 10
42. Gervin K, Page CM, Aass HC, Jansen MA, Fjeldstad HE, Andreassen BK, et al.
Cell type specific DNA methylation in cord blood: A 450K-reference data set
and cell count-based validation of estimated cell type composition.
Epigenetics. 2016;11(9):690–8.
43. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Stat Soc Ser B Methodol.
1995;57(1):289–300.
44. Suderman M, Staley JR, French R, Arathimos R, Simpkin A, Tilling K. dmrff:
identifying differentially methylated regions efficiently with power and
control. bioRxiv. 2018. https://www.biorxiv.org/content/biorxiv/early/201
8/12/31/508556.full.pdf:508556.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Geurtsen et al. Clinical Epigenetics            (2020) 12:3 Page 10 of 10
